Integra LifeSciences Holdings (IART)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	1,087,920	1,132,290	1,723,380	1,742,020	1,395,820	1,419,620	1,333,410	1,337,210	1,300,490	1,381,140	1,385,540	1,389,930	1,388,680	1,387,430	1,386,180	1,484,910	1,408,220	1,414,000	1,472,320	1,478,190
Total stockholders’ equity	US$ in thousands	1,545,280	1,521,590	1,534,200	1,597,950	1,587,880	1,579,220	1,683,160	1,674,940	1,804,400	1,724,410	1,660,920	1,615,200	1,684,800	1,631,690	1,574,980	1,529,330	1,514,870	1,397,990	1,349,100	1,341,800
Debt-to-capital ratio		0.41	0.43	0.53	0.52	0.47	0.47	0.44	0.44	0.42	0.44	0.45	0.46	0.45	0.46	0.47	0.49	0.48	0.50	0.52	0.52

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $1,087,920K ÷ ($1,087,920K + $1,545,280K)
= 0.41

The debt-to-capital ratio for Integra LifeSciences Holdings has shown a fluctuating trend over the analyzed periods. From March 31, 2020, to December 31, 2024, the ratio has ranged from 0.42 to 0.53.

The ratio decreased from 0.52 in March 31, 2020, to 0.45 in June 30, 2022, before slightly increasing again. Notably, there was a significant decrease in the ratio to 0.41 in December 31, 2024. This could indicate an improvement in the company's debt management and capital structure during this period.

Overall, a decreasing trend in the debt-to-capital ratio suggests that the company may be relying less on debt financing relative to its capital structure over time, which could be seen as a positive signal for investors and creditors. However, it's essential to consider other financial metrics and factors to have a comprehensive understanding of Integra LifeSciences Holdings' financial health.